Freshwater ascomycetes from southern Australia: Melanascomaceae fam. nov., Melanascoma panesporagen. et. sp. nov., and Pleurotheciumbruniussp. nov.

IF 0.2 4区医学 Q4 Medicine Drugs of The Future Pub Date : 2023-06-01 Epub Date: 2023-05-25 DOI:10.3114/fuse.2023.11.07

S C Fryar, D E A Catcheside

{"title":"Freshwater ascomycetes from southern Australia: Melanascomaceae fam. nov., Melanascoma panesporagen. et. sp. nov., and Pleurotheciumbruniussp. nov.","authors":"S C Fryar, D E A Catcheside","doi":"10.3114/fuse.2023.11.07","DOIUrl":null,"url":null,"abstract":"During a survey of freshwater fungi in temperate southern Australia, two new taxa were found, Melanascoma panespora and Pleurothecium brunius. Morphological and molecular data place Melanascoma panespora in the Diaporthomycetidae representing a new genus. Melanascoma, along with Proliferophorum and Paraproliferophorum, form a new lineage and the family Melanascomaceae is introduced. Phylogenetic analyses using ITS, 28S, and 18S nrRNA gene sequences,, along with morphological examination revealed Pleurothecium brunius to be a new species of Pleurothecium, sister to P. aquaticum. Citation: Fryar SC, Catcheside DEA (2023). Freshwater ascomycetes from southern Australia: Melanascomaceae fam. nov., Melanascoma panespora gen. et. sp. nov., and Pleurothecium brunius sp. nov. Fungal Systematics and Evolution 11: 85-93. doi: 10.3114/fuse.2023.11.07.","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"21 1","pages":"85-93"},"PeriodicalIF":0.2000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10964405/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drugs of The Future","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3114/fuse.2023.11.07","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/5/25 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

During a survey of freshwater fungi in temperate southern Australia, two new taxa were found, Melanascoma panespora and Pleurothecium brunius. Morphological and molecular data place Melanascoma panespora in the Diaporthomycetidae representing a new genus. Melanascoma, along with Proliferophorum and Paraproliferophorum, form a new lineage and the family Melanascomaceae is introduced. Phylogenetic analyses using ITS, 28S, and 18S nrRNA gene sequences,, along with morphological examination revealed Pleurothecium brunius to be a new species of Pleurothecium, sister to P. aquaticum. Citation: Fryar SC, Catcheside DEA (2023). Freshwater ascomycetes from southern Australia: Melanascomaceae fam. nov., Melanascoma panespora gen. et. sp. nov., and Pleurothecium brunius sp. nov. Fungal Systematics and Evolution 11: 85-93. doi: 10.3114/fuse.2023.11.07.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

澳大利亚南部的淡水子囊菌：Melanascomaceae fam.

在对澳大利亚南部温带淡水真菌的调查中，发现了两个新的类群，即 Melanascoma panespora 和 Pleurothecium brunius。形态学和分子数据将 Melanascoma panespora 归入 Diaporthomycetidae，代表一个新属。Melanascoma 与 Proliferophorum 和 Paraproliferophorum 一起形成了一个新的品系，并引入了 Melanascomaceae 科。利用 ITS、28S 和 18S nrRNA 基因序列进行的系统发育分析以及形态学检查发现，Pleurothecium brunius 是 Pleurothecium 的一个新种，是 P. aquaticum 的姊妹。引用：Fryar SC, Catcheside DEA (2023).Fryar SC, Catcheside DEA (2023)：Melanascomaceae fam.Fungal Systematics and Evolution 11: 85-93. doi: 10.3114/fuse.2023.11.07.

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Drugs of The Future 医学-药学

CiteScore

0.30

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： A leading international, peer-reviewed biomedical research journal publishing articles on topics emerging from the confluence of fields including chemistry, biology, pharmacology, genomics and medicine, and addressed to scientists and researchers involved in drug design, discovery and development, target identification and validation, and the preclinical and clinical development of treatments for common as well as rare and neglected diseases and conditions. The journal publishes monographs containing comprehensive product information on new compounds in development, including synthesis, preclinical pharmacology, pharmacokinetics and metabolism, safety, clinical studies and drug interactions, as well as review articles on a variety of topics, congress and meeting reports.